Sandoz Group AG has agreed to pay approximately $450 million to settle all pending generic pricing litigation claims in the United States. The Swiss generic pharmaceuticals and biosimilars company reached settlement agreements with 43 US states and territories and indirect reseller plaintiffs without admitting wrongdoing. Under the state settlement, Sandoz will pay $400 million over seven years starting in 2027, plus an additional $50 million to states that settled earlier. The company also agreed to pay $28.5 million to resolve claims brought by the indirect reseller plaintiffs class. Sandoz stated that the settlements have no impact on its full-year 2026 guidance or mid-term outlook, though it increased its previously recognized provision to reflect the settlement amounts.
Sandoz Group AGSandoz agrees to pay $450 million to settle US generic drug pricing litigation, increasing its provision.